Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adagio Medical Holdings (ADGM) Accumulated Expenses (2023 - 2026)

Adagio Medical Holdings has reported Accumulated Expenses over the past 4 years, most recently at $7.1 million for Q1 2026.

  • Quarterly Accumulated Expenses rose 130.33% to $7.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $7.1 million through Mar 2026, up 130.33% year-over-year, with the annual reading at $1.5 million for FY2025, 41.53% down from the prior year.
  • Accumulated Expenses was $7.1 million for Q1 2026 at Adagio Medical Holdings, up from $1.5 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $7.1 million in Q1 2026 and troughed at $5000.0 in Q2 2024.
  • The 4-year median for Accumulated Expenses is $2.6 million (2024), against an average of $2.7 million.
  • The largest YoY upside for Accumulated Expenses was 67180.0% in 2025 against a maximum downside of 41.53% in 2025.
  • A 4-year view of Accumulated Expenses shows it stood at $3.0 million in 2023, then decreased by 13.98% to $2.6 million in 2024, then tumbled by 41.53% to $1.5 million in 2025, then soared by 365.17% to $7.1 million in 2026.
  • Per Business Quant, the three most recent readings for ADGM's Accumulated Expenses are $7.1 million (Q1 2026), $1.5 million (Q4 2025), and $1.6 million (Q3 2025).